MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 [Yahoo! Finance]
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: Yahoo! Finance
th Annual Meeting on November 6-10, 2024, in Houston, Texas. The presentations will showcase new preclinical data from MiNK's iNKT cell programs, agenT-797 and PRAME-TCR. Presentation Details Title: AgenT-797 cell therapy can be combined with next-generation immune checkpoint inhibitors (ICI) and / or bi-specific engagers to improve anticancer response Abstract Number: Date: Friday, November 8 th Title: PRAME-TCR iNKT cell therapy: Opportunity for best-in-class off-the-shelf solid tumor therapy targeting PRAME Abstract Number: Session Date: Saturday November 9 th About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and repr
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial ReportGlobeNewswire
- MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024GlobeNewswire
- MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of DirectorsGlobeNewswire
- MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors [Yahoo! Finance]Yahoo! Finance
INKT
Earnings
- 8/13/24 - Beat
INKT
Analyst Actions
- 10/9/24 - HC Wainwright
INKT
Sec Filings
- 10/31/24 - Form 8-K
- 10/18/24 - Form 8-K
- 9/13/24 - Form 8-K
- INKT's page on the SEC website